Gastric bypass in morbid obese patients is associated with reduction in adipose tissue inflammation via N-oleoylethanolamide (OEA)-mediated pathways

Thrombosis and Haemostasis

Volumn 113, Issue 4, 2015, Pages 838-850

  Montecucco, Fabrizio ^a,b,c   Lenglet, Sébastien ^a   Quercioli, Alessandra ^a   Burger, Fabienne ^a   Thomas, Aurélien ^b   Lauer, Estelle ^d   da Silva, Analina Raquel ^a   Mach, François ^a   Vuilleumier, Nicolas ^b   Bobbioni Harsch, Elisabetta ^b   Golay, Alain ^b   Schindler, Thomas H ^e   Pataky, Zoltan ^b  

^a UNIVERSITY OF GENEVA   (Switzerland)

^b GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^c UNIVERSITY OF GENOA   (Italy)

^d UNIVERSITY OF LAUSANNE   (Switzerland)

^e JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Chemokine; Endocannabinoids; Obesity; Subcutaneous adipose tissue

Indexed keywords

2 ARACHIDONOYLGLYCEROL; ADIPOCYTOKINE; ANANDAMIDE; BETA CHEMOKINE; C REACTIVE PROTEIN; ENDOCANNABINOID; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LEPTIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MITOGEN ACTIVATED PROTEIN KINASE; MONOCYTE CHEMOTACTIC PROTEIN 1; N OLEOYLETHANOLAMINE; PALMIDROL; RANTES; RESISTIN; TUMOR NECROSIS FACTOR; AUTACOID; CCL2 PROTEIN, HUMAN; CCL2 PROTEIN, MOUSE; ETHANOLAMINE DERIVATIVE; LIPID; N-OLEOYLETHANOLAMINE; OLEIC ACID;

ADIPOSE TISSUE; ADULT; ARTICLE; BODY MASS; CASE CONTROL STUDY; CELL DIFFERENTIATION; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE EXPRESSION; HUMAN; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIQUID CHROMATOGRAPHY; MALE; OBESITY; PILOT STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; REAL TIME POLYMERASE CHAIN REACTION; SOFT TISSUE INFLAMMATION; STOMACH BYPASS; WESTERN BLOTTING; 3T3 CELL LINE; ADIPOCYTE; ANIMAL; BLOOD; ENZYME ACTIVATION; LONGITUDINAL STUDY; METABOLISM; MIDDLE AGED; MOUSE; OBESITY, MORBID; PANNICULITIS; SIGNAL TRANSDUCTION; SUBCUTANEOUS FAT; SWITZERLAND; TIME; TREATMENT OUTCOME; UNIVERSITY HOSPITAL; WEIGHT REDUCTION;

3T3-L1 CELLS; ADIPOCYTES; ADIPOKINES; ADULT; ANIMALS; CASE-CONTROL STUDIES; CHEMOKINE CCL2; ENDOCANNABINOIDS; ENZYME ACTIVATION; ETHANOLAMINES; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FEMALE; GASTRIC BYPASS; HOSPITALS, UNIVERSITY; HUMANS; INFLAMMATION MEDIATORS; INSULIN RESISTANCE; LIPIDS; LONGITUDINAL STUDIES; MALE; MICE; MIDDLE AGED; OBESITY, MORBID; OLEIC ACIDS; PANNICULITIS; PILOT PROJECTS; PROSPECTIVE STUDIES; SIGNAL TRANSDUCTION; SUBCUTANEOUS FAT; SWITZERLAND; TIME FACTORS; TREATMENT OUTCOME; WEIGHT LOSS;

EID: 84931281597     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH14-06-0506     Document Type: Article

References (38)

1. Lavie CJ, McAuley PA, Church TS, et al. Obesity and cardiovascular diseases: implications regarding fitness, fatness, and severity in the obesity paradox. J Am Coll Cardiol 2014; 63: 1345-1354.
2. Das SR, Alexander KP, Chen AY, et al. Impact of body weight and extreme obesity on the presentation, treatment, and in-hospital outcomes of 50,149 patients with ST-Segment elevation myocardial infarction results from the NCDR (National Cardiovascular Data Registry). J Am Coll Cardiol 2011; 58: 2642-2650.
3. Haslam DW, James WP. Obesity. Lancet 2005; 366: 1197-1209.
4. Lasselin J, Magne E, Beau C, et al. Adipose inflammation in obesity: relationship with circulating levels of inflammatory markers and association with surgeryinduced weight loss. J Clin Endocrinol Metab 2014; 99: E53-61.
5. Fain JN. Release of interleukins and other inflammatory cytokines by human adipose tissue is enhanced in obesity and primarily due to the nonfat cells. Vitam Horm 2006; 74: 443-477.
6. Park HS, Park JY, Yu R. Relationship of obesity and visceral adiposity with serum concentrations of CRP, TNF-alpha and IL-6. Diabetes Res Clin Pract 2005; 69: 29-35.
7. Patel P, Abate N. Role of subcutaneous adipose tissue in the pathogenesis of insulin resistance. J Obes 2013; 2013: 489187.
8. Quercioli A, Pataky Z, Vincenti G, et al. Elevated endocannabinoid plasma levels are associated with coronary circulatory dysfunction in obesity. Eur Heart J 2011; 32: 1369-1378.
9. Quercioli A, Montecucco F, Pataky Z, et al. Improvement in coronary circulatory function in morbidly obese individuals after gastric bypass-induced weight loss: relation to alterations in endocannabinoids and adipocytokines. Eur Heart J 2013; 34: 2063-2073.
10. Sugamura K, Sugiyama S, Nozaki T, et al. Activated endocannabinoid system in coronary artery disease and antiinflammatory effects of cannabinoid 1 receptor blockade on macrophages. Circulation 2009; 119: 28-36.
11. Montecucco F, Di Marzo V. At the heart of the matter: the endocannabinoid system in cardiovascular function and dysfunction. Trends Pharmacol Sci 2012; 33: 331-340.
12. Quercioli A, Pataky Z, Montecucco F, et al. Coronary vasomotor control in obesity and morbid obesity: contrasting flow responses with endocannabinoids, leptin, and inflammation. JACC Cardiovasc Imaging 2012; 5: 805-815.
13. DeFronzo RA, Tobin JD, Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol 1979; 237: E214-223.
14. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972; 18: 499-502.
15. Thomas A, Hopfgartner G, Giroud C, et al. Quantitative and qualitative profiling of endocannabinoids in human plasma using a triple quadrupole linear ion trap mass spectrometer with liquid chromatography. Rapid Commun Mass Spectrom 2009; 23: 629-638.
16. Lobo SM, Quinto BM, Oyama L, et al. TNF-α modulates statin effects on secretion and expression of MCP-1, PAI-1 and adiponectin in 3T3-L1 differentiated adipocytes. Cytokine 2012; 60: 150-156.
17. Kang M, Yan LM, Li YM, et al. Inhibitory effect of microRNA-24 on fatty acidbinding protein expression on 3T3-L1 adipocyte differentiation. Genet Mol Res 2013; 12: 5267-5277.
18. Ge Q, Maury E, Rycken L, et al. Endocannabinoids regulate adipokine production and the immune balance of omental adipose tissue in human obesity. Int J Obes 2013; 37: 874-880.
19. Ambrosino P, Soldovieri MV, Russo C, et al. Activation and desensitization of TRPV1 channels in sensory neurons by the PPARα agonist palmitoylethanolamide. Br J Pharmacol 2013; 168: 1430-1444.
20. Pacher P1, Kunos G. Modulating the endocannabinoid system in human health and disease--successes and failures. FEBS J 2013; 280: 1918-1943.
21. Godlewski G, Offertáler L, Wagner JA, et al. Receptors for acylethanolamides-GPR55 and GPR119. Prostaglandins Other Lipid Mediat 2009; 89: 105-111.
22. Montecucco F, Di Marzo V, da Silva RF, et al. The activation of the cannabinoid receptor type 2 reduces neutrophilic protease-mediated vulnerability in atherosclerotic plaques. Eur Heart J 2012; 33: 846-856.
23. Picard F, Kurtev M, Chung N, Topark-Ngarm A, Senawong T, Machado De Oliveira R, et al. Sirt1 promotes fat mobilization in white adipocytes by repressing PPAR-gamma. Nature 2004; 429: 771-776.
24. Rodríguez-Calvo R, Serrano L, Coll T, et al. Activation of peroxisome proliferator-activated receptor beta/delta inhibits lipopolysaccharide-induced cytokine production in adipocytes by lowering nuclear factor-kappaB activity via extracellular signal-related kinase 1/2. Diabetes 2008; 57: 2149-2157.
25. Chen B, Wei J, Wang W, Cui G, et al. Identification of signaling pathways involved in aberrant production of adipokines in adipocytes undergoing oxidative stress. Arch Med Res 2009; 40: 241-248.
26. Lee HY, Després JP, Koh KK. Perivascular adipose tissue in the pathogenesis of cardiovascular disease. Atherosclerosis 2013; 230: 177-184.
27. Azuma K, Katsukawa F, Oguchi S, et al. Correlation between serum resistin level and adiposity in obese individuals. Obes Res 2003; 11: 997-1001.
28. Haluzik MM, Lacinova Z, Dolinkova M, et al. Improvement of insulin sensitivity after peroxisome proliferator-activated receptor-alpha agonist treatment is accompanied by paradoxical increase of circulating resistin levels. Endocrinology 2006; 147: 4517-4524.
29. Iqbal N, Seshadri P, Stern L, et al. Serum resistin is not associated with obesity or insulin resistance in humans. Eur Rev Med Pharmacol Sci 2005; 9: 161-165.
30. Bluher M, Engeli S, Kloting N, et al. Dysregulation of the peripheral and adipose tissue endocannabinoid system in human abdominal obesity. Diabetes 2006; 55: 3053-3060.
31. Cote M, Matias I, Lemieux I, et al. Circulating endocannabinoid levels, abdominal adiposity and related cardiometabolic risk factors in obese men. Int J Obes 2007; 31: 692-699.
32. Montecucco F, Matias I, Lenglet S, et al. Regulation and possible role of endocannabinoids and related mediators in hypercholesterolemic mice with atherosclerosis. Atherosclerosis 2009; 205: 433-441.
33. Lumeng CN, Bodzin JL, Saltiel AR. Obesity induces a phenotypic switch in adipose tissue macrophage polarization. J Clin Invest 2007; 117: 175-184.
34. Martínez de Ubago M, García-Oya I, Pérez-Pérez A, et al. Oleoylethanolamide, a natural ligand for PPAR-alpha, inhibits insulin receptor signalling in HTC rat hepatoma cells. Biochim Biophys Acta 2009; 1791: 740-745.
35. González-Yanes C, Serrano A, Bermúdez-Silva FJ, et al. Oleylethanolamide impairs glucose tolerance and inhibits insulin-stimulated glucose uptake in rat adipocytes through p38 and JNK MAPK pathways. Am J Physiol Endocrinol Metab 2005; 289: E923-929.
36. McClain J, Hsu F, Brown E, et al. Pericardial adipose tissue and coronary artery calcification in the Multi-ethnic Study of Atherosclerosis (MESA). Obesity 2013; 21: 1056-1063.
37. Qatanani M, Tan Y, Dobrin R, et al. Inverse regulation of inflammation and mitochondrial function in adipose tissue defines extreme insulin sensitivity in morbidly obese patients. Diabetes 2013; 62: 855-863.
38. Arner E, Mejhert N, Kulyté A, et al. Adipose tissue microRNAs as regulators of CCL2 production in human obesity. Diabetes 2012; 61: 1986-1993.